利拉鲁肽调节骨代谢促进骨再生的研究进展

doi:10.13701/j.cnki.kqyxyj.2022.11.003

摘要/Abstract

摘要： 利拉鲁肽是一种治疗糖尿病的新型药物,具有降低血糖、控制体重的重要作用。近些年大量实验证明利拉鲁肽可以通过多种信号通路调节骨代谢和炎症反应,在骨质疏松症、糖尿病、牙周炎等多种疾病中起骨保护作用。本文将对利拉鲁肽影响骨代谢的机制及其在不同疾病中的促进成骨作用进行综述,为利拉鲁肽在口腔疾病中的治疗应用提供理论基础。

关键词: 利拉鲁肽, 免疫系统, 骨再生

Abstract: Liraglutide is a new drug in the treatment of diabetes, which plays an important role in reducing blood glucose and controlling body weight. In recent years, a large amount of experimental evidence has shown that liraglutide can regulate bone metabolism and inflammatory response through a variety of signaling pathways, which plays a bone protective role in osteoporosis, diabetes, periodontitis, and other diseases. This article reviews the mechanism of liraglutide affecting bone metabolism and its osteogenic effect in different diseases, which provides theoretical basis for the application of liraglutide in the treatment of oral diseases.

Key words: liraglutide, immune system, bone regeneration

朱思羽, 刘慧颖. 利拉鲁肽调节骨代谢促进骨再生的研究进展[J]. 口腔医学研究, 2022, 38(11): 1014-1017.

ZHU Siyu, LIU Huiying. Research Progress of Liraglutide Regulating Bone Metabolism and Promoting Bone Regeneration[J]. Journal of Oral Science Research, 2022, 38(11): 1014-1017.

参考文献

[1] Yousef CC, Thomas A, Matar MA, et al. Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Me-llitus: A real-world, observational study andbrief narrative review [J]. Diabetes Res Clin Pract, 2021, 177:108871.
[2] 薛莹,王雨,司方莹,等.利拉鲁肽对失重大鼠骨质疏松及骨髓间充质干细胞成骨细胞分化的影响[J].郑州大学学报,2021,56(1):16-21.
[3] 朱丽利,杨德圣,朱彪,等.利拉鲁肽促进犬骨髓间充质干细胞骨向分化的体外研究[J].口腔颌面修复学杂志,2018,19(1):44-47.
[4] Li Y, Fu H, Wang H, et al. GLP-1 promotes osteogenic differentiation of human AD-SCs via the Wnt/GSK-3β/β-catenin path-way [J]. Mol Cell Endocrinol, 2020, 515:110921.
[5] Sun Y, Liang Y, Li Z, et al. Liraglutide promotes osteoblastic differentiation in MC3T3-E1 cells by ERK5 pathway [J]. Int J Endocrinol, 2020, 2020:8821077.
[6] Hou HW, Xue P, Wang Y, et al. Liraglutide regulates proliferation, differentiation, andapoptosis of preosteoblasts through a signaling network of Notch/Wnt/Hedgehog signal-ing pathways [J]. Eur Rev Med Pharmacol Sci, 2020, 24(23):12408-12422.
[7] Wu X, Li S, Xue P, et al. Liraglutide inhibits the apoptosis of MC3T3-E1 cells induced by serum deprivation through cAMP/PKA/β-catenin and PI3K/AKT/GSK3β signaling pathways[J]. Mol Cells, 2018, 41(3):234-243.
[8] Pal S, Maurya SK, Chattopadhyay S, et al. The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts [J]. Biochem Pharmacol, 2019, 164:34-44.
[9] 杨明明,解合兰,朱慧静,等.利拉鲁肽对MC3T3-E1前成骨细胞增生分化过程中内质网应激的影响[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(5): 440-445.
[10] Delgado-Calle J, Bellido T. The osteocyte as a signaling cell [J]. Physiol Rev, 2022, 102(1):379-410.
[11] Zhou A, Wu B, Yu H, et al. Current understanding of osteoimmunology in certain osteoimmune diseases [J]. Front Cell Dev Biol, 2021, 9:698068.
[12] Yu J, Shi YC, Ping F, et al. Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating Trem2 in female type 1 diabetic mice: Findings from transcriptomics [J]. Front Endocrinol (Lausanne), 2021, 12:763646.
[13] Baek CH, Kim H, Moon SY, et al. Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells [J]. Life Sci, 2022, 292:120331.
[14] Moschovaki Filippidou F, Kirsch AH, Thelen M, et al. Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation [J]. Am J Pathol, 2020, 190(2):400-411.
[15] Navabi R, Negahdari B, Hajizadeh-Saffar E, et al. Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic nonhuman primate model [J]. Life Sci, 2021, 276:119374.
[16] Helmstádter J, Keppeler K, Aust F, et al. GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation [J]. Antioxidants (Basel), 2021, 10(8):1175.
[17] Zhang YS, Zheng YD, Yuan Y, et al. Effects of anti-diabetic drugs on fracture risk: A systematic review and network meta-analysis [J]. Front Endocrinol (Lausanne), 2021, 12:735824.
[18] Hygum K, Harsløf T, Jørgensen NR, et al. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial [J]. Bone, 2020, 132:115197.
[19] Mieczkowska A, Millar P, Chappard D, et al. Dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model [J]. Calcif Tissue Int, 2020, 107(3):281-293.
[20] Sedky AA. Improvement of cognitive function, glucose and lipid homeos-tasis and serum osteocalcin levels by liraglutide in diabetic rats [J]. Fundam Clin Pharmacol, 2021, 35(6):989-1003.
[21] Chen K, Wu R, Mo B, et al. Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density [J]. J Musculoskelet Neuronal Interact, 2021, 21(1):142-148.
[22] Model JFA, Lima MV, Ohlweiler R, et al. Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats [J]. Mol Cell Endocrinol, 2021, 524:111158.
[23] 裴敏钰.利拉鲁肽通过JAK2/STAT3信号通路影响糖尿病大鼠牙周炎的研究[D].兰州大学,2021.
[24] Zhang Y, Yuan X, Wu Y, et al. Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo [J]. J Dent, 2020, 94:103310.
[25] Sawada N, Adachi K, Nakamura N, et al. Glucagon-like peptide-1 receptor agonist liraglutide ameliorates the development of periodontitis [J]. J Diabetes Res, 2020, 2020:8843310.
[26] Mahmoud RH, Mohammed MA, Said ES, et al. Author correction: Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats[J]. Eur Rev Med Pharmacol Sci, 2022, 26(2):345.
[27] Ji J, Feng M, Niu X, et al. Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VS MCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR) [J]. Bioengineered, 2021, 12(1):8057-8066.
[28] Yu M, Huang J, Zhu T, et al. Liraglutide loaded PLGA/gelatin electrospun nanofibrous mats promote angiogenesis to accelerate diabetic wound healing via the modulation of miR-29b-3p [J]. Biomater Sci, 2020, 8(15):4225-4238.
[29] Meurot C, Martin C, Sudre L, et al. Lira-glutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis [J]. Sci Rep, 2022, 12(1):1567.